Donovan Michael Glancy - 14 May 2026 Form 4 Insider Report for COLLEGIUM PHARMACEUTICAL, INC (COLL)

Reporting relationship: Director
Issuer ticker: COLL
Reported as of: 14 May 2026
Net transaction value: $0
SEC form: 4
Accepted by SEC: 18 May 2026, 16:15:21 UTC
Source filing: View source filing
Reporting owner signature: /s/ Colleen Tupper as Attorney-In-Fact For Michael Donovan

Key filing fact

Donovan Michael Glancy filed Form 4 for COLLEGIUM PHARMACEUTICAL, INC (COLL) on 18 May 2026.

Key facts

This page summarizes Donovan Michael Glancy's Form 4 filing for COLLEGIUM PHARMACEUTICAL, INC (COLL).
1 reported transaction and 0 derivative rows are listed below.
Accepted by SEC: 18 May 2026, 16:15.

Change

No earlier filing in this sequence is available for direct comparison.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0002134015 Primary reporting owner

Glancy Donovan Michael

Relationship: Director
Address: C/O COLLEGIUM PHARMACEUTICAL, INC., 100 TECHNOLOGY CENTER DRIVE, STOUGHTON
Signature: /s/ Colleen Tupper as Attorney-In-Fact For Michael Donovan
Signature date: 18 May 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

COLL transaction

Common Stock

Award

Transaction value
Shares: +17,482
Change %
Price: $0.000000^*
Shares after: 17,482
Date: 14 May 2026
Ownership: Direct
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

Reflects the grant of restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of the Issuer's common stock. 8,741 of the RSUs vest on the earlier of May 14, 2027, or the date of the Issuer's 2027 Annual Meeting of Shareholders; 8,741 of the RSUs vest on May 14, 2027, in each case subject to the director's continued service with the Issuer. The RSUs will be settled on such date, or, upon the election of the director, on the earlier of the end of the director's service on the Board of Directors, the director's death or disability, or a change in control of the Issuer, in shares of the Issuer's common stock.